FIG. 1



Fv, variable regions, antigen binding domain
Fab
CH1
(Fab')2
Hinge, Core
CH2
Fc, constant regions, crystallizable fragment
Glycans
CH3

Fig. 2A



Man
Man
Man — GlcNAc — GlcNAc
1
GlcNAc — Man
Man
GlcNAc — Man
Man — GlcNAc — GlcNAc
2
Gal
GlcNAc — Man
GlcNAc — Man
Man — GlcNAc — GlcNAc
3
Gal — GlcNAc — Man
Gal — GlcNAc — Man
Man — GlcNAc — GlcNAc
4
Gal
Gal — GlcNAc — Man
Gal — GlcNAc — Man
Man — GlcNAc — GlcNAc
5
Gal — Gal — GlcNAc — Man
Gal — Gal — GlcNAc — Man
Man — GlcNAc — GlcNAc
6
Sia
Gal — GlcNAc — Man
Gal — GlcNAc — Man
Man — GlcNAc — GlcNAc
7
Sia — Gal — GlcNAc — Man
Sia — Gal — GlcNAc — Man
Man — GlcNAc — GlcNAc
8

Fig. 2B








	9
	10
	11
	12
	13
	14
	15

Fig. 2C



Man
Man
Fuc
Man
GlcNAc
GlcNAc
16
GlcNAc
Man
Fuc
Man
GlcNAc
GlcNAc
17
GlcNAc
Man
Gal
Fuc
Man
GlcNAc
GlcNAc
18
GlcNAc
Man
Gal
GlcNAc
Man
Fuc
Man
GlcNAc
GlcNAc
19
Gal
GlcNAc
Man
Gal
Gal
GlcNAc
Man
Fuc
Man
GlcNAc
GlcNAc
20
Gal
GlcNAc
Man
Gal
Gal
Gal
GlcNAc
Man
Fuc
Man
GlcNAc
GlcNAc
21
Gal
Gal
GlcNAc
Man
Gal
Gal
GlcNAc
Man
Sia
Gal
Fuc
Man
GlcNAc
GlcNAc
22
GlcNAc
Man
Gal
Sia
Gal
Fuc
Man
GlcNAc
GlcNAc
23
Gal
GlcNAc
Man
Sia
Gal
GlcNAc
Man

Fig. 2D








	24
	25
	26
	27
	28
	29
	30

Fig. 2E







	31
	32
	33
	34
	35
	36

Fig. 3

Fig 3A.




Fig 3B.





Figure 4.


Viable Cells/ml (x10^5)
30
25
20
15
10
5
0
0
48
96
144
192
240
288
336
384
Time (Hours)
C1083B-1
C1083B-12
C1083-H18
C1083-H21
C1083

C

Figure 5.




Fig. 6

Fig 6A.

ATGCGGGCATGGACTGGTTCCTGGCGTTGGATTATGCTCATTCTTTTTGCCTGGGGGACCTTGTTGTTTTATATAGGTGGTCATTTGGTT
CGAGATAATGACCACCCTGATCACTCTAGCAGAGAACTCTCCAAGATTCTTGCAAAGCTTGAACGCTTAAAACAACAAAATGAAGACT
TGAGGCGAATGGCTGAGTCTCTACGAATACCAGAAGGCCCCATTGACCAGGGGACGGCTACGGGAAGAGTCCGTGTTTTAGAAGAAC
AGCTTGTTAAGGCCAAAGAACAGATTGAAAATTACAAGAAACAAGCCAGAAATGGTCTGGGGAAGGATCATGAAATCTTAAGGAGGA
GGATTGAAAATGGAGCTAAAGAGCTCTGGTTTTTTCTACAAAGTGAACTGAAGAAATTAAAGCATTTAGAAGGAAATGAACTCCAAAG
ACATGCAGATGAAATTCTTTTGGATTTAGGACACCATGAAAGGTCTATCATGACGGATCTATACTACCTCAGTCAAACAGATGGAGCA
GGGGATTGGCGTGAAAAAGAGGCCAAAGATCTGACAGAGCTGGTCCAGCGGAGAATAACTTATCTCCAGAATCCCAAGGACTGCAGC
AAAGCCAGGAAGCTGGTGTGTAACATCAATAAGGGCTGTGGCTATGGTTGCCAACTCCATCACGTGGTCTACTGTTTCATGATTGCTTA
TGGCACCCAGCGAACA*CTCATCTTGGAATCTCAGAATTGGCGCTATGCTACTGGTGGATGGGAGACTGTG*TTTAGACCTGTAAGTGAGAC
ATGCACAGACAGATCTGGCCTCTCCACTGGACACTGGTCAGGTGAAGTGAATGACAAAAATATTCAAGTGGTGGAGCTCCCCATTGTA
GACAGCCTCCATCCTCGGCCTCCTTACTTACCACTGGCTGTTCCAGAAGACCTTGCAGATCGACTCGTAAGAGTCCATGGTGATCCTGC
AGTGTGGTGGGTGTCCCAGTTCGTCAAATATTTGATTCGTCCACAACCTTGGCTAGAAAAGGAAATAGAAGAAGCCACCAAGAAGCTT
GGCTTCAAACATCCAGTCA*TTGGAGTCCATGTCAGACGCACAGACA*AAGTGGGAACAGAGGCAGCCTTCCATCCCATCGAAGAGTACAT
GGTACATGTTGAAGAACATTTTCAGCTTCTCGCACGCAGAATGCAAGTGGATAAAAAAAGAGTATATCTGGCTACCGATGACCCTGCT
TTGTTAAAGGAGGCAAAGACAAAGTAA

Fig 6B.




Fig. 7

Fig 7A.




Fig 7B.




Fig. 8

Fig. 8A




Fig. 8B




Fig. 9

Fig. 9A




Fig. 9B




Fig. 10A



% Specific Lysis
120
100
80
60
40
20
0
CNTO 859
CNTO 860
CNTO 860 YB2/0
media alone
1% Triton X
1ug/mL
0.1ug/mL
0.01ug/mL
0.001ug/mL
0.0001ug/mL
0.00001ug/mL

FIG. 10B





% Specific Lysis
100
80
60
40
20
0
CNTO 860
CNTO 860 YB2/0
YB2/0 A4-2
0.5% TritonX-100
100 ng/mL
10 ng/mL
1 ng/mL
100 pg/mL
10 pg/mL
1 pg/mL
0.1 pg/mL
0.01 pg/mL
0.001 pg/mL

Fig. 11A.




CNTO 860 control (463A)

FIG. 11B




CNTO 860 (YB2/0)

Fig. 11C




CNTO 860 (YB2/0 c1261A)

Fig. 12A




148 control (NS/0)

Fig. 12B



148 #2 (YB2/0 1083B)

Fig. 12C



148 #1 (YB2/0 1083C)

Fig. 13





% Specific lysis
100
50
0
10^{-5}
10^{-4}
10^{-3}
10^{-2}
10^{-1}
10^{0}
Ab concentration (µg/ml)
CNTO 148 from C1083C YB2/0
CNTO 148 from C1083B YB2/0
CNTO 148 from mouse myeloma
CNTO 148 Gno control
CNTO 6234 huG1 control

Fig. 14



2C11 (YB2/0)

Fig. 15


% of CD8+ cells that were CD25+
50
40
30
20
10
0
0.01
0.1
1
Dose (mg/kg)
2C11 huG1, HEK (~90% fucose)
2C11 huG1, C1083B (~40% fucose)
2C11 huG1, C1083C (~15% fucose)
PBS
2C11 huG1 Gno